研报掘金丨光大证券：维持云南白药“增持”评级，加速推进核药研发

格隆汇2025-08-04

光大证券研报指出，7月16日，由云南白药集团全资子公司云核医药（天津）有限公司研发的1.1类创新核药INR102注射液顺利完成I/IIa期临床试验首例受试者入组给药，标志着该药物进入临床研究新阶段。目前1.1 类创新核药INR101注射液是云核医药研发的放射性诊断药物，已进入III期临床试验；1.1类创新核药INR102注射液是放射性治疗药物，已启动I/IIa期临床试验。化药1类新药JZ-14胶囊...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2556011806?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-08-04 16:06","share_image_url":"https://static.laohu8.com/6b8fa6424aebe95f6781d04ef17a1852","id":"2556011806","market":"sh","top_or_hot":-1,"title":"研报掘金丨光大证券：维持云南白药“增持”评级，加速推进核药研发","media":"格隆汇","content":"<div>\n<p>光大证券研报指出，7月16日，由云南白药集团全资子公司云核医药（天津）有限公司研发的1.1类创新核药INR102注射液顺利完成I/IIa期临床试验首例受试者入组给药，标志着该药物进入临床研究新阶段。目前1.1 类创新核药INR101注射液是云核医药研发的放射性诊断药物，已进入III期临床试验；1.1类创新核药INR102注射液是放射性治疗药物，已启动I/IIa期临床试验。化药1类新药JZ-14胶囊...</p>\n\n<a href=\"https://www.gelonghui.com/rss/live/live.xml\">网页链接</a>\n\n</div>\n","source":"live_gelonghui","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>研报掘金丨光大证券：维持云南白药“增持”评级，加速推进核药研发</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n研报掘金丨光大证券：维持云南白药“增持”评级，加速推进核药研发\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-08-04 16:06 北京时间&nbsp;&nbsp;&nbsp;<a href=https://www.gelonghui.com/rss/live/live.xml><strong>格隆汇</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>光大证券研报指出，7月16日，由云南白药集团全资子公司云核医药（天津）有限公司研发的1.1类创新核药INR102注射液顺利完成I/IIa期临床试验首例受试者入组给药，标志着该药物进入临床研究新阶段。目前1.1 类创新核药INR101注射液是云核医药研发的放射性诊断药物，已进入III期临床试验；1.1类创新核药INR102注射液是放射性治疗药物，已启动I/IIa期临床试验。化药1类新药JZ-14胶囊...</p>\n\n<a href=\"https://www.gelonghui.com/rss/live/live.xml\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4204","symbol_name":"教育服务","start_time":0,"source_url":"https://www.gelonghui.com/rss/live/live.xml","article_id":"2556011806","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2556011806","pubTimestamp":1754294801,"columns":[],"sourceInfo":{"source_id":"live_gelonghui","name":"格隆汇"},"weMediaInfo":null,"summary":"光大证券研报指出，7月16日，由云南白药集团全资子公司云核医药（天津）有限公司研发的1.1类创新核药INR102注射液顺利完成I/IIa期临床试验首例受试者入组给药，标志着该药物进入临床研究新阶段。目","collect":0,"end_time":0,"defaultTopTitle":"gelonghui.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"159938":"医药","601788":"光大证券","BK4204":"教育服务","BK0164":"国企混改","BK1515":"抗疫概念","BK0196":"行业龙头","BK1574":"生物医药B类股","BK0239":"医药制造","000538":"云南白药","BK0183":"MSCI概念","09939":"开拓药业-B","BK0188":"融资融券","BK0012":"证金概念","BK0187":"一线龙头","BK0028":"国家队","JZ":"见知教育","BK4134":"信息科技咨询与其它服务","BK0276":"资本市场","BK1161":"生物科技","BK0175":"白马股","III":"信息服务"},"translate_title":"Research Report Nuggets | Everbright Securities: Maintain Yunnan Baiyao's \"overweight\" rating and accelerate nuclear drug research and development","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159938":1,"601788":1,"000538":1,"JZ":1,"09939":1,"III":1},"content_text":"光大证券研报指出，7月16日，由云南白药集团全资子公司云核医药（天津）有限公司研发的1.1类创新核药INR102注射液顺利完成I/IIa期临床试验首例受试者入组给药，标志着该药物进入临床研究新阶段。目前1.1 类创新核药INR101注射液是云核医药研发的放射性诊断药物，已进入III期临床试验；1.1类创新核药INR102注射液是放射性治疗药物，已启动I/IIa期临床试验。化药1类新药JZ-14胶囊获批临床，用于治疗溃疡性结肠炎，该产品是First-in-Class的小分子免疫调节剂。此外，公司引进抗体药物KA-1641的相关专利，目前处于临床前研究开发阶段。公司聚焦核心主业，全链提质增效，重视研发创新和数智化转型，战略引领中长期发展。考虑到降本增效成果显著，小幅上调25-26年归母净利润预测为52.71/ 58.49亿元（较上次上调2%/2%）, 新增27年归母净利润预测64.92亿元，当前股价对应PE 为19/17/15倍，维持“增持”评级。","kind":"live","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":true,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2556011806","isCrawlerRequest":true}